Investment Rating - The report maintains an "Outperform" rating for the industry [6] Core Insights - Chuangjian Medical successfully developed type III recombinant human collagen protein, which aligns with the amino acid sequence of natural human collagen and has a natural triple helix structure, enabling industrialization [2][3] - The market currently features products primarily made from humanized collagen, with human collagen being scarce. The National Medical Products Administration categorizes recombinant collagen into three levels, with human collagen being the highest [3] - Chuangjian Medical has initiated clinical trials for aesthetic implant agents and has made significant technological breakthroughs in stable genetic expression systems and fermentation purification technology [3] - The successful development of type III recombinant human collagen protein is expected to advance the commercialization of high-performance fillers with excellent anti-aging properties and low immunogenicity [3] Summary by Relevant Sections Market Dynamics - The report highlights the growth potential in the collagen-based skincare and filler product sectors, emphasizing the importance of upstream and downstream companies in this market [4] - Key players such as Juzhi Biotechnology and Jinbo Biotechnology are noted for their strong performance and innovative products in the collagen market [4][11] Company Developments - Juzhi Biotechnology reported over 1.6 billion in revenue for 2022, with a projected 2 billion+ for 2023, showcasing significant growth [4] - Jinbo Biotechnology anticipates a net profit of 280-300 million for 2023, reflecting a year-on-year increase of 156%-175% [4] - Jiangsu Wuzhong's subsidiary has received approval for a facial filler, indicating growth opportunities in regenerative injectables [11] - Chuangjian Medical has received approval for type II medical devices and is focusing on anti-aging skincare products [11] - Other companies like Marubi and Juyuan Biotechnology are also making strides in the collagen market with innovative products and significant investments planned for the future [11]
商贸零售行业动态点评:创健医疗成功研发Ⅲ型重组人胶原蛋白,关注功效型护肤及针剂商业化进程
East Money Securities·2024-02-21 16:00